echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huahai Pharmaceutical's subsidiaries Huaaotai Bio and Huabo Bio HB0028 Injection were approved for clinical use

    Huahai Pharmaceutical's subsidiaries Huaaotai Bio and Huabo Bio HB0028 Injection were approved for clinical use

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Huaaotai Bio and Huabo Bio, the subsidiaries of Huahai Pharmaceutical, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Drug Administration for HB0028 injection


    HB0028 is a bispecific antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor-beta (TGF-beta)


    In addition, the HB0028 project fused the TGF-β type II receptor with the C-terminus of the anti-PD-L1 antibody, which overcomes the problem that the fusion of the TGF-β type II receptor with the N-terminus of the anti-PD-L1 antibody is prone to produce O sugars.


    At present, there are no similar drugs targeting both PD-L1 and TGF-β on the market


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.